The announcement of the first patient dosing in a clinical trial is a significant milestone for any pharmaceutical company. It indicates that the company's product has passed initial safety checks and is now being tested for efficacy. This could potentially boost investor confidence in Kura Oncology's clinical development program, leading to a positive impact on the company's stock price in the short term.